# UK Preclinical Imaging Market

> UK Preclinical Imaging Market Research Report: Size, Share, Trend Analysis By Product (Optical Imaging, Nuclear Imaging, Micro-MRI, Micro-Ultrasound, Micro-CT, Photoacoustic Imaging System) and By Distribution Channel (Optical, Nuclear, CT Contrast Agents, MRI Contrast Agents) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.9%
- **2024:** $ 186.38 Million
- **2025:** $ 197.37 Million
- **2035:** $ 350 Million
- **Key Players:** Bruker Corporation (US), PerkinElmer Inc. (US), Siemens Healthineers (DE), GE Healthcare (US), Fujifilm Holdings Corporation (JP), Miltenyi Biotec (DE), Thermo Fisher Scientific Inc. (US), Mediso Medical Imaging Systems (HU), Aspect Imaging (IL)

**Report ID:** MRFR/MED/48495-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/uk-preclinical-imaging-market-50252

---

## Market Summary

## **UK Preclinical Imaging Market Overview**

As per MRFR analysis, the UK Preclinical Imaging Market Size was estimated at 173.25 (USD Million) in 2023. The UK Preclinical Imaging Market Industry is expected to grow from 186.38(USD Million) in 2024 to 463.4 (USD Million) by 2035. The UK Preclinical Imaging Market CAGR (growth rate) is expected to be around 8.633% during the forecast period (2025 - 2035)

**Key UK Preclinical Imaging Market Trends Highlighted**

The UK Preclinical Imaging Market is currently undergoing some important changes which mark the growth shift of biomedical research and drug development industry. One important market constraint is the demand for more sophisticated imaging systems to increase the accuracy of preclinical studies. There is a growing use of MRI, PET, and CT among UK researchers to get a deeper understanding of disease mechanisms which support the evolving state legislation to enhance drug testing and efficacy evaluations. Another trend is the increase in research and development funding from both public and private institutions.

This is driven by the need to fulfil the legislative measures to boost Britain’s Innovation and Healthcare System improvements, as put forth by life sciences government initiatives. Such funding is creating opportunities for technological development and partnerships between the academia and industries in the field imaging references and modalities computer scientists design for better disease monitoring and detection. Other opportunities available in UK Preclinical Imaging Market include implementation of artificial intelligence and machine learning technologies to imaging systems. These technologies improve and facilitate data analysis and workflow processes, which is essential given the work involved in preclinical studies.

The movement toward personalized medicine is also increasing the need for advanced imaging methods that can capture specific details for tailored treatment strategies. Recently, the UK has been experiencing a shift towards more collaborative research activities, including those directed at the creation of imaging devices appropriate for rare disease investigations. This emphasizes the need for combined work to translate preclinical results into clinical practice and, therefore, the strong imaging frameworks required by research facilities.

This information as a whole paints a picture of the UK Preclinical Imaging Market as one that is responsive to change and full of innovations, collaboration, and improvement of healthcare services.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**UK Preclinical Imaging Market Drivers**

**Increase in Research and Development Activities**

The UK Preclinical Imaging Market Industry is experiencing significant growth due to a surge in Research and Development activities. The UK government has allocated substantial funding to support biomedical research, with a 15% increase in Research and Development investment observed in the healthcare sector. Organizations such as the UK Research and Innovation and The Wellcome Trust play crucial roles in advancing innovative imaging techniques that enhance preclinical studies.

This funding enables researchers to develop advanced imaging modalities, facilitating the study of complex biological processes and accelerating the development of new therapies. The increase in the number of biomedical research projects, backed by government initiatives, directly contributes to the growth of the UK Preclinical Imaging Market Industry.

**Rising Incidence of Chronic Diseases**

The growing incidence of chronic diseases, especially cancer, is a pivotal driver for the UK Preclinical Imaging Market Industry. Recent statistics reveal that approximately 367,000 new cancer cases were recorded in the UK in 2019, which indicates a rising trend. Organizations such as Cancer Research UK have reported a continuing increase in cancer diagnoses and emphasize the urgent need for effective early detection methods. 

Preclinical imaging technologies are instrumental in understanding the disease mechanisms and the evaluation of therapeutic strategies.This heightened focus on cancer research in the UK is stimulating demand for advanced imaging techniques in preclinical studies.

**Advancements in Imaging Technologies**

Continual advancements in imaging technologies are significantly impacting the UK Preclinical Imaging Market Industry. Innovations such as 3D imaging, high-resolution magnetic resonance imaging (MRI), and molecular imaging techniques are revolutionizing the preclinical landscape. The UK government supports these technological advancements through various initiatives that encourage collaboration between academia and industry. 

For instance, the establishment of innovation hubs and research centers has facilitated access to cutting-edge imaging equipment, enhancing the capabilities of research institutions in the UK.This integration of advanced technology into preclinical research is paramount in understanding disease pathology, leading to the development of more targeted therapies.

**UK Preclinical Imaging Market Segment Insights**

**Preclinical Imaging Market Product Insights**

The UK Preclinical Imaging Market is a vital sector that supports Research and Development in biomedical science, focusing on various imaging technologies essential for preclinical studies. The market comprises segments such as Optical Imaging, Nuclear Imaging, Micro-MRI, Micro-Ultrasound, Micro-CT, and Photoacoustic Imaging Systems, each contributing uniquely to the field of preclinical research.

Optical Imaging utilizes light for visualization, facilitating real-time imaging of biological processes, which is crucial in studying drug efficacy and disease progression.This technology is gaining traction due to its non-invasive nature and the ability to provide high-resolution images, thus playing a significant role in the early stages of drug development. 

Nuclear Imaging offers unique insights by tracking the distribution of radioactive tracers within living organisms, making it invaluable for evaluating physiological processes and monitoring therapeutic interventions. The Micro-MRI segment is particularly notable because it allows for detailed imaging of small animal models, offering high spatial resolution and contrast which are essential for assessing complex biological systems.Micro-Ultrasound provides a real-time imaging solution with the advantage of being portable and cost-effective, enhancing its appeal in both academic and clinical settings. 

Meanwhile, Micro-CT excels in providing high-resolution 3D images of preclinical models, which is essential for precise anatomical assessment and volumetric analysis. Finally, the Photoacoustic Imaging Systems combine optical and ultrasound technologies, allowing researchers to study tissue in greater detail by detecting optical signals generated by absorbed light. This multifaceted approach increases the ability to monitor biological functions, making it a robust choice for non-invasive measurements.The growth drivers for these technologies in the UK include advancements in imaging technologies, increasing investments in biopharmaceutical R&D, and a growing emphasis on personalized medicine. 

However, challenges such as high equipment costs and the need for skilled personnel to interpret complex imaging data may hinder market growth. Nevertheless, the increasing application of these imaging modalities in drug discovery, cancer research, and genetic studies presents significant opportunities for expansion in the sector. Overall, the product segment within the UK Preclinical Imaging Market is characterized by innovation and continuous technological advancements, continually shifting the landscape of preclinical research.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Preclinical Imaging Market Distribution Channel Insights**

The UK Preclinical Imaging Market is experiencing a significant transformation across its Distribution Channel segment, which includes Optical, Nuclear, CT Contrast Agents, and MRI Contrast Agents. This segment is crucial as it directly impacts the accessibility and efficiency of advanced imaging technologies within the region. Optical imaging technologies are emerging due to their non-invasive nature and ability to provide real-time imaging, thus catering to the increased demand for efficient research and diagnostic solutions. 

The Nuclear imaging segment plays a vital role in oncology research, offering high sensitivity for detecting tumor cells, which aligns with the UK's growing focus on cancer research initiatives.Similarly, CT Contrast Agents are instrumental in enhancing the quality of imaging results, which is essential for improving diagnostic accuracy in preclinical studies. MRI Contrast Agents are also critical in neurological research, providing essential insights into the brain's structure and function. 

The dynamics of these distribution channels reflect the ongoing advancements in imaging techniques, which are pivotal for the UK’s Research and Development landscape, driven by the need for innovative solutions in medical diagnostics and treatment efficacy.

**UK Preclinical Imaging Market Key Players and Competitive Insights**

Competitive insights of the UK Preclinical Imaging Market reveal a landscape characterized by a blend of innovative technologies, strategic partnerships, and a focus on enhancing imaging methodologies to support drug development and biomedical research. This market has seen a surge in demand as researchers and pharmaceutical companies look for reliable imaging solutions to better understand biological processes, track disease progression, and evaluate treatment efficacy in preclinical studies. Technological advancements in imaging modalities, particularly in modalities such as MRI, PET, CT, and optical imaging, have paved the way for more precise animal studies, influencing the competitive dynamics. 

The market is defined by key players that strive to provide cutting-edge imaging solutions while navigating regulatory challenges and adapting to the specific needs of the UK research community, ultimately fostering a highly competitive environment.Mediso has established a robust presence in the UK Preclinical Imaging Market, leveraging its strengths in innovative imaging technology to cater specifically to the needs of researchers and clinicians. With a portfolio that emphasizes the integration of multimodal imaging systems, Mediso facilitates enhanced visualization and quantification of biological processes in vivo.

Its commitment to advancing imaging solutions, such as hybrid imaging systems that combine different modalities, positions the company favorably against its competitors. 

Moreover, Mediso's collaboration with academic and research institutions in the UK further enhances its foothold in the market, allowing it to tailor its offerings to address local demands effectively. The company’s strong reputation for reliability and technical support underscores its competitive edge, which is grounded in quality and customer-centric service tailored to the UK’s unique requirements.Merck KGaA has a prominent role in the UK Preclinical Imaging Market, recognized for its comprehensive range of imaging products and services designed to support drug development and scientific research. 

The company provides advanced imaging solutions that include reagents and imaging agents tailored for various modalities such as PET and MRI. Merck KGaA's strategic focus on enhancing the capabilities of its imaging technologies allows researchers to obtain accurate and reproducible results, which is crucial for preclinical studies. 

Its strengths lie in a well-established distribution network within the UK, strong customer relationships, and significant investments in research and development to innovate its product offerings. Additionally, Merck KGaA has pursued mergers and acquisitions that have strengthened its market position, enabling the company to expand its product portfolio and enhance its technological capabilities in preclinical imaging, further positioning itself as a leader in this competitive landscape.

**Key Companies in the UK Preclinical Imaging Market Include**

**UK Preclinical Imaging Market Industry Developments**

The UK Preclinical Imaging Market is currently witnessing significant advancements and developments. Companies like Mediso, Merck KGaA, PerkinElmer, and GE Healthcare are seeing growth in their market valuation, which is positively impacting research capabilities and efficiencies in the field. Recently, in September 2023, Merck KGaA announced a strategic collaboration with a leading UK university to enhance imaging technologies for drug development and disease research. Similarly, Bruker is making strides with new imaging modalities, focusing on enhanced resolution and imaging speed that were showcased at a national conference in March 2023. 

In terms of mergers and acquisitions, in August 2023, Fujifilm completed the acquisition of a small imaging technology firm in the UK to bolster its presence in preclinical imaging technologies, further consolidating its market share. Additionally, regulatory advancements initiated by the UK government to streamline approvals for imaging devices are expected to accelerate innovation in this sector. Overall, these developments underscore a dynamic landscape in the UK's preclinical imaging market, with stakeholders aiming to improve research efficiencies and outcomes through enhanced imaging capabilities.

**UK Preclinical Imaging Market Segmentation Insights**

## Market Drivers

### Integration of Artificial Intelligence

The integration of artificial intelligence (AI) into imaging technologies is transforming the preclinical imaging market. AI algorithms are being developed to enhance image analysis, improve accuracy, and reduce the time required for data interpretation. This technological advancement appears to be a game-changer, as it allows researchers to extract more meaningful insights from imaging data. The potential for AI to streamline workflows and enhance productivity is likely to attract more investment into the preclinical imaging market. As AI continues to evolve, its applications in preclinical imaging may expand, further driving market growth and innovation.

### Expansion of Biopharmaceutical Research

The preclinical imaging market is benefiting from the expansion of biopharmaceutical research in the UK. As the biopharmaceutical sector continues to grow, there is an increasing need for advanced imaging technologies to support drug discovery and development processes. The UK government has invested heavily in biopharmaceutical initiatives, with funding exceeding £1 billion in recent years. This investment is likely to enhance the capabilities of preclinical imaging, facilitating more efficient and effective research. Consequently, the preclinical imaging market is poised for growth, as biopharmaceutical companies seek to leverage imaging technologies to improve their research outcomes.

### Growing Emphasis on Regulatory Compliance

The preclinical imaging market is increasingly influenced by the growing emphasis on regulatory compliance in research practices. Regulatory bodies are placing greater scrutiny on the methodologies used in preclinical studies, necessitating the adoption of advanced imaging techniques that meet stringent standards. This trend is prompting researchers to invest in high-quality imaging technologies that can provide reliable and reproducible results. As compliance becomes a critical factor in the approval process for new drugs, the preclinical imaging market is expected to expand, driven by the need for technologies that align with regulatory expectations.

### Rising Demand for Non-Invasive Techniques

The preclinical imaging market is experiencing a notable increase in demand for non-invasive imaging techniques. Researchers and pharmaceutical companies are increasingly prioritising methods that minimise harm to animal subjects while providing accurate data. This shift is driven by ethical considerations and regulatory pressures, as well as the need for reliable results in drug development. The market for non-invasive imaging modalities, such as MRI and PET, is projected to grow significantly, with estimates suggesting a CAGR of around 8% over the next few years. This trend indicates a robust future for the preclinical imaging market, as stakeholders seek to balance scientific advancement with ethical responsibility.

### Increased Funding for Research Initiatives

The preclinical imaging market is witnessing a surge in funding for research initiatives, particularly in the fields of oncology and neurology. Government and private sector investments are being directed towards innovative imaging technologies that can provide deeper insights into disease mechanisms. Recent reports indicate that funding for preclinical research in the UK has increased by approximately 15% over the past year, reflecting a growing recognition of the importance of imaging in drug development. This influx of capital is likely to bolster the preclinical imaging market, enabling the development of cutting-edge imaging solutions that can accelerate research timelines.

## Future Outlook

The [Preclinical Imaging Market](https://www.marketresearchfuture.com/reports/preclinical-imaging-market-7365) is projected to grow at a 5.9% CAGR from 2025 to 2035, driven by technological advancements, increasing R&D investments, and rising demand for personalized medicine.

**New opportunities:**

- Development of AI-driven imaging software for enhanced diagnostic accuracy.
- Expansion of imaging services in contract research organizations (CROs).
- Integration of multimodal imaging systems for comprehensive preclinical studies.

By 2035, the preclinical imaging market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Product: Optical Imaging (Largest) vs. Nuclear Imaging (Fastest-Growing)

In the UK preclinical imaging market, Optical Imaging holds the largest share, primarily due to its widespread application in various research fields such as oncology and neurology. Following closely, Nuclear Imaging is rapidly gaining traction, fueled by advancements in radionuclide technologies and a growing focus on personalized medicine. Other technologies like Micro-MRI, Micro-Ultrasound, Micro-CT, and Photoacoustic Imaging Systems contribute to the diverse landscape, yet they currently represent smaller market segments.

Growth trends indicate that while Optical Imaging continues to maintain its dominance, Nuclear Imaging is expected to experience the highest growth rates in the coming years. This can be attributed to increased investments in R&D, rising demand for non-invasive imaging techniques, and the expansion of imaging services in research institutions. Furthermore, innovations in imaging agents and systems are likely to propel the adoption of various imaging technologies within the UK preclinical imaging market.

Optical Imaging (Dominant) vs. Micro-CT (Emerging)

Optical Imaging has established itself as the dominant technology in the UK preclinical imaging market due to its versatility and efficacy in capturing high-resolution images. It is widely utilized in various applications such as cancer research and drug discovery, allowing researchers to visualize biological processes in real-time. On the other hand, Micro-CT is emerging as a significant player with its ability to provide detailed 3D imaging at microscale resolutions. Its growing adoption is driven by its application in bone structure analysis and soft tissue imaging, positioning Micro-CT as a vital tool in preclinical research. The competitive landscape indicates a trend toward integrating these technologies to enhance imaging capabilities, ensuring comprehensive data collection in preclinical studies.

### By Reagents: Optical (Largest) vs. MRI Contrast Agents (Fastest-Growing)

In the UK preclinical imaging market, the share distribution among reagents reveals that Optical agents hold the largest segment due to their widespread application and familiarity in research settings. This is followed by MRI Contrast Agents, which, while not as dominant, play a crucial role due to their advanced capabilities in imaging soft tissues, making them essential in neurological studies.

Growth trends indicate that while Optical agents maintain a stronghold, MRI Contrast Agents are rapidly gaining traction, particularly as innovations in imaging technology evolve. Factors driving this growth include the increasing demand for non-invasive imaging techniques and the expansion of research endeavors requiring advanced imaging modalities. Additionally, investments in biotechnology research are fostering a favorable environment for MRI Contrast Agents to flourish.

Optical (Dominant) vs. MRI Contrast Agents (Emerging)

Optical agents have established themselves as the dominant choice in the reagents segment of the UK preclinical imaging market, attributable to their ease of use, cost-effectiveness, and versatility across various imaging applications. These agents are essential for many preclinical studies, facilitating high-resolution imaging with minimal sample disturbance. In contrast, MRI Contrast Agents are emerging as a compelling option, especially for research focusing on soft tissue visualization. The advancements in formulation and the development of novel MRI agents designed to enhance imaging specificity position these agents as critical tools for future clinical and research applications. Their growing preference among researchers showcases a shift towards more sophisticated imaging techniques that promise better diagnostic accuracy.

## Competitive Benchmarking

The preclinical imaging market exhibits a dynamic competitive landscape, characterized by rapid technological advancements and a growing emphasis on precision medicine. Key players such as Bruker Corporation (US), Siemens Healthineers (DE), and Thermo Fisher Scientific Inc. (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Bruker Corporation (US) focuses on developing high-resolution imaging systems, while Siemens Healthineers (DE) emphasizes integrating AI into imaging technologies, thereby enhancing diagnostic capabilities. Thermo Fisher Scientific Inc. (US) is actively pursuing collaborations with research institutions to expand its product offerings and improve customer engagement, collectively shaping a competitive environment that prioritizes technological superiority and customer-centric solutions.The market structure appears moderately fragmented, with several players vying for market share through localized manufacturing and optimized supply chains. Companies are increasingly localizing their production to reduce lead times and enhance responsiveness to regional demands. This strategy not only mitigates supply chain disruptions but also allows for tailored solutions that meet specific market needs. The collective influence of these key players fosters a competitive atmosphere where innovation and operational efficiency are paramount.

In October  Siemens Healthineers (DE) announced a strategic partnership with a leading AI firm to develop advanced imaging algorithms aimed at improving diagnostic accuracy. This collaboration is poised to enhance Siemens' product portfolio, enabling the integration of cutting-edge AI technologies into their imaging systems. The strategic importance of this move lies in its potential to set Siemens apart in a market increasingly driven by AI capabilities, thereby attracting a broader customer base seeking advanced diagnostic solutions.

In September  Thermo Fisher Scientific Inc. (US) launched a new preclinical imaging platform designed to facilitate real-time monitoring of disease progression in animal models. This platform is expected to streamline research processes and improve data accuracy, which is crucial for drug development. The launch signifies Thermo Fisher's commitment to innovation and positions the company as a leader in providing comprehensive imaging solutions that cater to the evolving needs of researchers.

In August  Bruker Corporation (US) expanded its product line by introducing a novel imaging modality that combines MRI and PET technologies. This innovative approach aims to provide researchers with enhanced imaging capabilities, allowing for more detailed insights into biological processes. The strategic importance of this development lies in its potential to attract a diverse clientele, including academic institutions and pharmaceutical companies, thereby reinforcing Bruker's competitive edge in the market.

As of November  current trends in the preclinical imaging market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaborative innovation in enhancing their competitive positions. Looking ahead, it is likely that competitive differentiation will evolve from traditional price-based strategies to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of agility and responsiveness in meeting the demands of a rapidly changing market.

## Recent News & Developments

The UK Preclinical Imaging Market is currently witnessing significant advancements and developments. Companies like Mediso, Merck KGaA, PerkinElmer, and GE Healthcare are seeing growth in their market valuation, which is positively impacting research capabilities and efficiencies in the field. Recently, in September 2023, Merck KGaA announced a strategic collaboration with a leading UK university to enhance imaging technologies for drug development and disease research. Similarly, Bruker is making strides with new imaging modalities, focusing on enhanced resolution and imaging speed that were showcased at a national conference in March 2023. 

In terms of mergers and acquisitions, in August 2023, Fujifilm completed the acquisition of a small imaging technology firm in the UK to bolster its presence in preclinical imaging technologies, further consolidating its market share. Additionally, regulatory advancements initiated by the UK government to streamline approvals for imaging devices are expected to accelerate innovation in this sector. Overall, these developments underscore a dynamic landscape in the UK's preclinical imaging market, with stakeholders aiming to improve research efficiencies and outcomes through enhanced imaging capabilities.

## Report Scope

| MARKET SIZE 2024 | 186.38(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 197.37(USD Million) |
| MARKET SIZE 2035 | 350.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.9% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Bruker Corporation (US), PerkinElmer Inc. (US), Siemens Healthineers (DE), GE Healthcare (US), Fujifilm Holdings Corporation (JP), Miltenyi Biotec (DE), Thermo Fisher Scientific Inc. (US), Mediso Medical Imaging Systems (HU), Aspect Imaging (IL) |
| Segments Covered | Product, Reagents |
| Key Market Opportunities | Advancements in imaging technologies enhance drug development efficiency in the preclinical imaging market. |
| Key Market Dynamics | Technological advancements drive innovation in preclinical imaging, enhancing research capabilities and regulatory compliance in the UK. |
| Countries Covered | UK |

## Frequently Asked Questions

**Q: What is the current valuation of the UK preclinical imaging market?**
A: The market valuation was $186.38 Million in 2024.

**Q: What is the projected market size for the UK preclinical imaging market by 2035?**
A: The market is projected to reach $350.0 Million by 2035.

**Q: What is the expected CAGR for the UK preclinical imaging market during the forecast period 2025 - 2035?**
A: The expected CAGR is 5.9% during the forecast period.

**Q: Which companies are considered key players in the UK preclinical imaging market?**
A: Key players include Bruker Corporation, PerkinElmer Inc., Siemens Healthineers, and GE Healthcare.

**Q: What segment had the highest valuation in the UK preclinical imaging market in 2024?**
A: Micro-CT had the highest valuation at $70.0 Million in 2024.

**Q: What is the valuation range for Optical Imaging in the UK preclinical imaging market?**
A: The valuation range for Optical Imaging is between $30.0 Million and $55.0 Million.

**Q: How do Nuclear Imaging and Micro-MRI compare in terms of market valuation?**
A: Nuclear Imaging was valued between $25.0 Million and $45.0 Million, while Micro-MRI ranged from $35.0 Million to $65.0 Million.

**Q: What is the projected growth for CT Contrast Agents in the UK preclinical imaging market by 2035?**
A: CT Contrast Agents are expected to grow to a valuation between $50.0 Million and $90.0 Million by 2035.

**Q: What is the valuation range for Photoacoustic Imaging Systems in 2024?**
A: Photoacoustic Imaging Systems had a valuation range of $36.38 Million to $75.0 Million in 2024.

**Q: What are the expected trends in the UK preclinical imaging market regarding reagents?**
A: Reagents, particularly MRI Contrast Agents, are projected to grow from $66.38 Million to $130.0 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-preclinical-imaging-market-50252*